Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Radiotherapy, Intensity-Modulated | 1 | 2019 | 129 | 0.580 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 5 | 2016 | 231 | 0.520 |
Why?
|
| Bone Neoplasms | 1 | 2019 | 231 | 0.520 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 7 | 2016 | 1052 | 0.460 |
Why?
|
| Patient Selection | 1 | 2016 | 663 | 0.410 |
Why?
|
| Rectal Neoplasms | 1 | 2013 | 136 | 0.400 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2016 | 1368 | 0.350 |
Why?
|
| Lung Neoplasms | 7 | 2016 | 2344 | 0.340 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2016 | 759 | 0.340 |
Why?
|
| Protein Kinase Inhibitors | 5 | 2016 | 891 | 0.340 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2016 | 759 | 0.260 |
Why?
|
| Lactams, Macrocyclic | 2 | 2016 | 49 | 0.250 |
Why?
|
| Carbazoles | 2 | 2015 | 84 | 0.240 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2013 | 1266 | 0.230 |
Why?
|
| Piperidines | 2 | 2015 | 199 | 0.210 |
Why?
|
| Neoplasms | 1 | 2016 | 2470 | 0.190 |
Why?
|
| Pyrimidines | 3 | 2016 | 459 | 0.140 |
Why?
|
| Eligibility Determination | 1 | 2016 | 63 | 0.130 |
Why?
|
| Aged, 80 and over | 2 | 2019 | 7086 | 0.130 |
Why?
|
| Age Distribution | 1 | 2016 | 372 | 0.120 |
Why?
|
| Sex Distribution | 1 | 2016 | 359 | 0.120 |
Why?
|
| Pyrazoles | 2 | 2016 | 405 | 0.120 |
Why?
|
| Informed Consent | 1 | 2016 | 170 | 0.120 |
Why?
|
| Scleroderma, Localized | 1 | 2015 | 8 | 0.120 |
Why?
|
| Aged | 5 | 2019 | 22103 | 0.120 |
Why?
|
| Pemetrexed | 1 | 2015 | 32 | 0.120 |
Why?
|
| Acrylamides | 1 | 2015 | 58 | 0.120 |
Why?
|
| Meningeal Carcinomatosis | 1 | 2013 | 8 | 0.110 |
Why?
|
| Meningeal Neoplasms | 1 | 2015 | 93 | 0.110 |
Why?
|
| Antineoplastic Agents | 2 | 2015 | 2061 | 0.110 |
Why?
|
| Spinal Neoplasms | 1 | 2013 | 29 | 0.110 |
Why?
|
| Prognosis | 3 | 2016 | 3794 | 0.110 |
Why?
|
| Neoplasm Staging | 2 | 2013 | 1295 | 0.100 |
Why?
|
| SEER Program | 1 | 2013 | 206 | 0.100 |
Why?
|
| Gene Rearrangement | 1 | 2013 | 148 | 0.100 |
Why?
|
| Lymphatic Metastasis | 1 | 2013 | 320 | 0.100 |
Why?
|
| Pyridines | 1 | 2015 | 478 | 0.100 |
Why?
|
| ErbB Receptors | 1 | 2015 | 607 | 0.090 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2013 | 857 | 0.090 |
Why?
|
| Middle Aged | 7 | 2016 | 31154 | 0.090 |
Why?
|
| Treatment Outcome | 2 | 2016 | 10230 | 0.090 |
Why?
|
| Mutation | 3 | 2016 | 3717 | 0.090 |
Why?
|
| Male | 8 | 2019 | 63681 | 0.090 |
Why?
|
| Prevalence | 1 | 2016 | 2564 | 0.080 |
Why?
|
| Survival Rate | 1 | 2013 | 1877 | 0.080 |
Why?
|
| Cohort Studies | 1 | 2019 | 5420 | 0.080 |
Why?
|
| United States | 2 | 2016 | 13903 | 0.070 |
Why?
|
| Adult | 5 | 2016 | 35576 | 0.070 |
Why?
|
| Brain Neoplasms | 1 | 2015 | 1171 | 0.070 |
Why?
|
| Lactams | 2 | 2016 | 21 | 0.060 |
Why?
|
| Humans | 10 | 2019 | 129650 | 0.060 |
Why?
|
| Aminopyridines | 2 | 2016 | 97 | 0.060 |
Why?
|
| Sulfones | 2 | 2016 | 108 | 0.060 |
Why?
|
| Female | 7 | 2016 | 68776 | 0.060 |
Why?
|
| Cell Line, Tumor | 2 | 2016 | 3215 | 0.040 |
Why?
|
| Dermatitis | 1 | 2015 | 19 | 0.030 |
Why?
|
| Liver Failure | 1 | 2015 | 91 | 0.030 |
Why?
|
| Molecular Structure | 1 | 2015 | 482 | 0.030 |
Why?
|
| Cell Survival | 1 | 2016 | 1086 | 0.030 |
Why?
|
| Binding Sites | 1 | 2015 | 1252 | 0.020 |
Why?
|
| Hyperglycemia | 1 | 2015 | 328 | 0.020 |
Why?
|
| Liver Neoplasms | 1 | 2015 | 640 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 2012 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2015 | 964 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2016 | 2391 | 0.020 |
Why?
|